These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17768137)

  • 1. Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
    Jin Z; Ran M; Man Z
    Haematologica; 2007 Sep; 92(9):e82-4. PubMed ID: 17768137
    [No Abstract]   [Full Text] [Related]  

  • 2. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 3. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
    Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
    Wang H; Cao F; Li J; Li L; Li Y; Shi C; Lan W; Li D; Zhao H; Zhang Y; Zhang Z; Liu X; Meng R; Yang B; Zhou J
    Blood; 2014 Sep; 124(12):1998-2000. PubMed ID: 24963041
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
    Spencer A; Firkin F
    Aust N Z J Med; 1999 Jun; 29(3):385-6. PubMed ID: 10868510
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
    Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
    Au WY; Ma SK; Ooi C; Liang R; Kwong YL
    J Clin Oncol; 2000 Oct; 18(19):3435-7. PubMed ID: 11013284
    [No Abstract]   [Full Text] [Related]  

  • 11. Ancient remedy performs new tricks.
    Mervis J
    Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
    [No Abstract]   [Full Text] [Related]  

  • 12. [Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia].
    Colin O; Julian A; Puyade M; Bouyer S; Meurin E; Blondeau S; Houeto JL; Neau JP
    Rev Med Interne; 2016 Dec; 37(12):844-848. PubMed ID: 27020402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
    Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
    Asou N
    Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Tamm I; Paternostro G; Zapata JM
    N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL
    Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
    Tajima M
    Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.